{"id":510886,"date":"2020-10-09T21:10:02","date_gmt":"2020-10-09T21:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=510886"},"modified":"2020-10-09T21:10:02","modified_gmt":"2020-10-09T21:10:02","slug":"global-rituximab-biosimilars-market-value-expected-to-reach-262-billion-by-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-rituximab-biosimilars-market-value-expected-to-reach-262-billion-by-2023_510886.html","title":{"rendered":"Global Rituximab Biosimilars Market Value Expected To Reach $2.62 Billion By 2023"},"content":{"rendered":"
\"Global<\/a><\/p>\n
\n
Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change<\/div>\n<\/div>\n<\/div>\n
Pfizer Inc Is One Of The Largest Players In The Rituximab Biosimilars Market, According To The Business Research Company\u2019s Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change<\/p>\n<\/div>\n

(Companies Covered: Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko)<\/em><\/p>\n

The global rituximab biosimilars market is expected to decline from $1.84 billion in 2019 to $1.78 billion in 2020 at a compound annual growth rate of -3.22%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $2.62 billion in 2023 at a compound annual growth rate of 13.85%. <\/p>\n

Read More On The Global Rituximab Biosimilars Market Report At –
<\/strong>https:\/\/www.thebusinessresearchcompany.com\/report\/rituximab-biosimilars-global-market-report-2020-30-covid-19-growth-and-change<\/a><\/p>\n

The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA). <\/p>\n

Global Rituximab Biosimilars Market Segmentation – <\/strong>
1) By Application:<\/strong> Non-Hodgkin’s lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid arthritis, Others.
2) Hospital Pharmacy:<\/strong> Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels.<\/p>\n

Global Rituximab Biosimilars Market Driver –
<\/strong>The companies operating in the biosimilars market are continuously focusing on new product development in collaborations with other companies in the industry. Innovation through partnerships is shaping the rituximab biosimilars market.<\/p>\n

Request For A Sample Of The Global Rituximab Biosimilars Market Report At – <\/strong>
https:\/\/www.thebusinessresearchcompany.com\/sample.aspx?id=3430&type=smp<\/a><\/p>\n

Few Points From The Global Rituximab Biosimilars Market TOC<\/strong>
1. Executive Summary
2. Rituximab Biosimilars Market Characteristics
3. Rituximab Biosimilars Market Size And Growth
3.1. Global Rituximab Biosimilars Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
4. Rituximab Biosimilars Market Segmentation
4.1. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Rituximab Biosimilars Market Regional And Country Analysis
5.1. Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6. Asia-Pacific Rituximab Biosimilars Market
6.1. Asia-Pacific Rituximab Biosimilars Market Overview
7. China Rituximab Biosimilars Market
7.1. China Rituximab Biosimilars Market Overview<\/p>\n

Interested to know more about The Business Research Company? <\/strong> <\/p>\n

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Business Research Company<\/a>
Contact Person:<\/strong> Oliver Guirdham
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +44 20 7193 0708
Address:<\/strong>
City:<\/strong> London
State:<\/strong> Greater London
Country:<\/strong> United Kingdom
Website:<\/strong> https:\/\/www.thebusinessresearchcompany.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change Pfizer Inc Is One Of The Largest Players In The Rituximab Biosimilars Market, According To The Business Research Company\u2019s Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-510886","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/510886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=510886"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/510886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=510886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=510886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=510886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}